Robert Hoffman
Psychiatry · Woodland Hills, CANPI 1780841536
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,600 of the $7,667 with a category attached, or 73.0%. 26 manufacturers reported payments, led by Eisai Inc. at 28.6% of the total. Reporting peaked in 2021 at $3,070 and has fallen 73.4% since, to $817 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$2K
- AbbVie$1K
- Bausch Health US, LLC$622
- Supernus Pharmaceuticals, Inc.$547
- Vanda Pharmaceuticals Inc.$459
- Lundbeck LLC$283
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$1,99826%
- Food & beverage$5,60073%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 12 | $2,194 |
| AbbVie(2 entities) | 71 | $1,381 |
| Bausch Health US, LLC | 47 | $622 |
| Supernus Pharmaceuticals, Inc. | 30 | $547 |
| Vanda Pharmaceuticals Inc. | 20 | $459 |
| Lundbeck LLC | 12 | $283 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $262 |
| Axsome Therapeutics, Inc. | 14 | $250 |
| Otsuka America Pharmaceutical, Inc. | 10 | $213 |
| Johnson & Johnson | 12 | $205 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $178 |
| Alkermes, Inc. | 6 | $144 |
| Merck | 6 | $135 |
| Sunovion Pharmaceuticals Inc. | 8 | $119 |
| Almatica Pharma LLC | 4 | $105 |
| Avanir Pharmaceuticals, Inc. | 5 | $104 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $100 |
| Biohaven Pharmaceuticals, Inc. | 2 | $63 |
| Ironshore Pharmaceuticals Inc. | 3 | $61 |
| Idorsia Pharmaceuticals US Inc | 3 | $55 |
| Adlon Therapeutics L.p. | 3 | $55 |
| Arbor Pharmaceuticals, Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Noven Therapeutics, LLC | 1 | $24 |
| Assertio Therapeutics, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dayvigo$1,998
How this compares
$7,667 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProvigilModafinil | 12 | $69,690 |
| VraylarCariprazine Hcl | 29 | $42,862 |
| RexultiBrexpiprazole | 15 | $26,674 |
| TrintellixVortioxetine Hydrobromide | 38 | $22,231 |
| FetzimaLevomilnacipran Hcl | 26 | $14,006 |
| Doxepin Hcl | 35 | $10,488 |
| GraliseGabapentin | 12 | $10,164 |
| XanaxAlprazolam | 12 | $9,474 |
| DayvigoLemborexant | 26 | $8,675 |
| BelsomraSuvorexant | 13 | $5,709 |
| Vilazodone Hcl | 31 | $5,312 |
| MydayisDextroamphetamine/Amphetamine | 12 | $3,997 |
| Bupropion XlBupropion Hcl | 126 | $3,508 |
| Oxcarbazepine | 39 | $2,526 |
| Zaleplon | 73 | $2,320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $1,381 | $56,86855 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $213 | $26,67415 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $262 | $22,23138 claims |
| Almatica Pharma LLCGralise | $105 | $10,16412 claims |
| Eisai Inc.Dayvigo | $2,194 | $8,67526 claims |
| MerckBelsomra | $135 | $5,70913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Woodland Hills
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.